Home/Pipeline/NG004

NG004

Spinal Cord Injury

Phase 1Active

Key Facts

Indication

Spinal Cord Injury

Phase

Phase 1

Status

Active

Company

Neurimmune

About Neurimmune

Neurimmune is a Swiss, privately-held biotech founded in 2006, specializing in discovering and developing first-in-class antibody therapeutics for protein aggregation diseases. Its core Reverse Translational Medicine™ platform analyzes immune cells from elderly donors to generate fully human antibodies with high selectivity and low immunogenicity risk. The company has built a diversified clinical-stage pipeline targeting ATTR-CM, ALS, and Alzheimer's, advancing programs through strategic partnerships with major pharma while retaining early-stage innovation autonomy.

View full company profile

Therapeutic Areas

Alzheimer's Disease Amyotrophic Lateral Sclerosis ATTR Cardiomyopathy Spinal Cord Injury Systemic Amyloidosis

Other Spinal Cord Injury Drugs

Drug	Company	Phase	Status
MSC‑SCI	Advancells	Phase 1	Active
itNSCs	Stemedica Cell Technologies	Development	Active
MAP4343	Mapreg	Preclinical	Active
Spinal Cord Injury Program	BioAxone Biosciences	Clinical	Active
Undisclosed Scaffold Program	Innervace	Pre-clinical	Active
Q-Cells	Q Therapeutics	Research	Active
APOSEC	Aposcience	Pre-clinical	Active
Perineline™	NeuroSolv Therapeutics	Phase 1	Active
Nogo-A Receptor Blocking Antibody	NovaGo Therapeutics	Phase 1b	Active
Spinal Cord Injury (SCI) Neural Bridge	Matricelf	Preclinical	Active